---
figid: PMC4463189__JCI76094.f3
figlink: /pmc/articles/PMC4463189/figure/F3/
number: F3
caption: Dual blockade within the MAPK pathway or between the MAPK and parallel PI3K
  pathways improves clinical outcome by reducing compensatory signaling and delaying
  the onset of resistance. Mut, mutation; OE, overexpression; LOH, loss of heterozygosity;
  ↓Exp, decreased expression.
pmcid: PMC4463189
papertitle: Targeting cancer with kinase inhibitors.
reftext: Stefan Gross, et al. J Clin Invest. 2015 May 1;125(5):1780-1789.
pmc_ranked_result_index: '23870'
pathway_score: 0.9492187
filename: JCI76094.f3.jpg
figtitle: Targeting cancer with kinase inhibitors
year: '2015'
organisms: Homo sapiens
ndex: 7ea1031d-def0-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4463189__JCI76094.f3.html
  '@type': Dataset
  description: Dual blockade within the MAPK pathway or between the MAPK and parallel
    PI3K pathways improves clinical outcome by reducing compensatory signaling and
    delaying the onset of resistance. Mut, mutation; OE, overexpression; LOH, loss
    of heterozygosity; ↓Exp, decreased expression.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MAPK1
  - AKT3
  - AKT1
  - FOXO3
  - MAP2K2
  - MTOR
  - FOXO4
  - MAP2K1
  - FOXO1
  - NRAS
  - MUT
  - PIK3CA
  - AKT2
  - MAPK3
  - KRAS
  - FOXO6
  - HRAS
  - Selumetinib
  - Trametinib
  - Dabrafenib
  - Cobimetinib
  - Cancer
genes:
- word: ERK1/2
  symbol: ERK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: FOXO
  symbol: FOXO
  source: bioentities_symbol
  hgnc_symbol: FOXO3
  entrez: '2309'
- word: MEK1/2
  symbol: MEK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: FOXO
  symbol: FOXO
  source: bioentities_symbol
  hgnc_symbol: FOXO4
  entrez: '4303'
- word: MEK1/2
  symbol: MEK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: FOXO
  symbol: FOXO
  source: bioentities_symbol
  hgnc_symbol: FOXO1
  entrez: '2308'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: Mut,
  symbol: MUT
  source: hgnc_symbol
  hgnc_symbol: MUT
  entrez: '4594'
- word: PIK3CA
  symbol: PIK3CA
  source: hgnc_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: ERK1/2
  symbol: ERK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: FOXO
  symbol: FOXO
  source: bioentities_symbol
  hgnc_symbol: FOXO6
  entrez: '100132074'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
chemicals:
- word: Selumetinib
  source: MESH
  identifier: C517975
- word: Trametinib
  source: MESH
  identifier: C560077
- word: Dabrafenib
  source: MESH
  identifier: C561627
- word: Cobimetinib
  source: MESH
  identifier: C574276
diseases:
- word: Cancer
  source: ''
  identifier: ''
figid_alias: PMC4463189__F3
redirect_from: /figures/PMC4463189__F3
figtype: Figure
---
